News

Celon Pharma S.A. has finalised another part of the phase I clinical trial for its esketamine-based drug. The centre conducting the study confirmed that the course of this part of the trial is in accordance with the assumptions defined in the clinical protocol. Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: Participants receivedRead more »

250 participants: scientists and entrepreneurs, 3 days of debates and meetings on the most important challenges in the area of health and innovation in Europe, including representatives of Celon Pharma. The biggest meeting of this year was aimed at developing the main pillars of the EIT Health agenda in 2018/2019. Jerzy Pieczykolan, PhD, Head ofRead more »

Maciej Wieczorek, CEO was a guest of the Impact CEE conference . A series of such meetings is attended by representatives of national research institutes, Polish and international companies, the public administration and representatives of start-ups. The subject of the first debate was the biotech industry, it took place on 19 February 20118 at theRead more »

Yet another year in a row, Maciej Wieczorek was ranked on the 100 most influential people in Polish healthcare in 2017 list prepared by Puls Medycyny. The ranking was announced on 5 February this year. The editors of Puls Medycyny presented the judges with over 300 nominees for evaluation. The jury panel was composed ofRead more »

Celon Pharma S.A. concluded an agreement with Biotechpharma on industrial development of the anti-VEGF protein – a generic to Lucentis (ranibizumab) in line with GMP for the purpose of clinical trials. The positive results of the work we carried out so far as well as over PLN 24 million of co-funding from the National CentreRead more »

Information received from the study centre confirms its course in accordance with the schedule and assumptions in terms of patient safety as defined in the clinical protocol approved by the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. In the first part of the phase 1 trial were administered a drug doseRead more »

Aleksandra Stańczak, PhD, Leader of the Oncology Research Team took part in the 7th edition of the conference: “Cancer Molecular Biology in Clinical Practice”, which was held at the end of November 2017 in Warsaw. At the: conference Ms Stańczak presented the most important assumptions of the project:  CELONKO – Development of modern biomarkers andRead more »

The procedure included: Sweden, Finland, Norway, Denmark and Iceland. The Company’s business partner in the scope of obtaining marketing authorisation and product distribution in the markets covered by the DCP is Glenmark. The countries covered by the Scandinavian procedure have issued positive decisions on acceptance of the submitted marketing authorisation dossier. Bogdan Manowski, Director forRead more »